Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429755 | 0.91 | HTT (0.52) | KDRMMP13MAPK1HTT | |
| SCHEMBL3055165 | 0.85 | KDM5B (0.49) | KDRFLT1PLAU | |
| SCHEMBL429462 | 0.83 | KDR (0.71) | KDRFLT1MAPK1 | |
| SCHEMBL476382 | 0.80 | PGK1 (0.38) | STAT6 | |
| SCHEMBL429454 | 0.80 | KDR (0.73) | KDRFLT1MAPK1 | |
| SCHEMBL429478 | 0.79 | KDR (0.75) | KDRFLT1 | |
| SCHEMBL14515126 | 0.77 | KDR (0.40) | KDRFLT1HTTPLAU | |
| SCHEMBL429466 | 0.77 | KDR (0.60) | KDRFLT1 | |
| SCHEMBL3057584 | 0.75 | L3MBTL1 (0.40) | MAPK1HTT | |
| SCHEMBL427507 | 0.73 | KDR (0.69) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | KDR 2406/4885MMP13 2819/4885FLT1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.